| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0...
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target ...
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target fro...
VIZZ sample distribution initiated nationwide to Eye Care ProfessionalsCommercial product shipments to be initiated in October ...
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...